Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ihsan Ates

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Journal of Infection in Developing Countries|February 22, 2022
Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19 patientsAhmet Omma, Abdulsamet Erden, Hakan Apaydin, et al.
Human Vaccines & Immunotherapeutics|June 26, 2024
The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac -inactivated COVID-19 vaccinesMine Durusu Tanriover, Ozlem Altuntas Aydin, Rahmet Guner, et al.
Vaccines|February 24, 2024
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-UpZafer Sezer, Shaikh Terkis Islam Pavel, Ahmet Inal, et al.
Journal of Perinatal Medicine|May 3, 2023
Adverse outcomes and maternal complications in pregnant women with severe-critical COVID-19: a tertiary center experienceSelcan Sinaci, Atakan Tanacan, Berhan Besimoglu, et al.
Vaccine|December 2, 2022
Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trialsAykut Ozdarendeli, Zafer Sezer, Shaikh Terkis Islam Pavel, et al.
The Journal of Obstetrics and Gynaecology Research|December 30, 2022
The utility of systemic immune-inflammation index and systemic immune-response index in the prediction of adverse outcomes in pregnant women with coronavirus disease 2019: Analysis of 2649 casesAtakan Tanacan, Deniz Oluklu, Bergen Laleli Koc, et al.
Human Vaccines & Immunotherapeutics|October 31, 2022
Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trialAhmet Omma, Ayse Batirel, Mehtap Aydin, et al.
Vaccines|July 29, 2023
Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical StudyIhsan Ates, Ayse Batirel, Mehtap Aydin, et al.
Journal of Infection and Public Health|March 1, 2021
Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravirRahmet Guner, Imran Hasanoglu, Bircan Kayaaslan, et al.
Frontiers in Medicine|October 31, 2022
Effect of chronic lung diseases on mortality of prevariant COVID-19 pneumonia patientsHatice Kilic, Emine Arguder, Aysegul Karalezli, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Journal of Infection in Developing Countries|February 22, 2022
Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19 patientsAhmet Omma, Abdulsamet Erden, Hakan Apaydin, et al.
Human Vaccines & Immunotherapeutics|June 26, 2024
The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac -inactivated COVID-19 vaccinesMine Durusu Tanriover, Ozlem Altuntas Aydin, Rahmet Guner, et al.
Vaccines|February 24, 2024
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-UpZafer Sezer, Shaikh Terkis Islam Pavel, Ahmet Inal, et al.
Journal of Perinatal Medicine|May 3, 2023
Adverse outcomes and maternal complications in pregnant women with severe-critical COVID-19: a tertiary center experienceSelcan Sinaci, Atakan Tanacan, Berhan Besimoglu, et al.
Vaccine|December 2, 2022
Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trialsAykut Ozdarendeli, Zafer Sezer, Shaikh Terkis Islam Pavel, et al.
The Journal of Obstetrics and Gynaecology Research|December 30, 2022
The utility of systemic immune-inflammation index and systemic immune-response index in the prediction of adverse outcomes in pregnant women with coronavirus disease 2019: Analysis of 2649 casesAtakan Tanacan, Deniz Oluklu, Bergen Laleli Koc, et al.
Human Vaccines & Immunotherapeutics|October 31, 2022
Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trialAhmet Omma, Ayse Batirel, Mehtap Aydin, et al.
Vaccines|July 29, 2023
Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical StudyIhsan Ates, Ayse Batirel, Mehtap Aydin, et al.
Journal of Infection and Public Health|March 1, 2021
Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravirRahmet Guner, Imran Hasanoglu, Bircan Kayaaslan, et al.
Frontiers in Medicine|October 31, 2022
Effect of chronic lung diseases on mortality of prevariant COVID-19 pneumonia patientsHatice Kilic, Emine Arguder, Aysegul Karalezli, et al.
Pageof 9